Trend
DailyUptrend (confirmed)
4 hourExpanding
1 hourStrong Bearish
15 minSymmetric Triangle
5 minStrong Bearish
Daily trend turns down below $7.78
Key levels
Resistance$7.05
Resistance$5.11
Support$4.09
Support$2.82
Latest news & SEC filings
SEC FilingExagen Inc. filed an insider trading report (Form 4)
LegalHolder of 10% stake in Exagen flags short-swing trade profit
AnalystCanaccord Genuity keeps Buy rating on Exagen, cuts price target to $9
All XGN news →Exagen is a medical technology company that develops and sells blood-based testing products for autoimmune and rheumatic diseases under its AVISE brand. Its flagship test, AVISE CTD, helps clinicians diagnose connective tissue diseases such as lupus and rheumatoid arthritis. The company primarily serves rheumatologists and other physicians in the United States through its specialty laboratory.
Based on the company's 10-K filed Mar 10, 2026.
Nasdaq · Healthcare
SEPT Low Target
$8.00
SEPT Mid Target
$11.00
SEPT High Target
$12.00
Analyst Consensus
$11.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for XGN.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$8.58
32
Moat Score
NONE
3/9
Piotroski Score
-4.7
Altman Z-Score
Insider Signal
SELLING
1 buys / 4 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Chernett Jorey | 10% owner | Buy | 7,085 | $37K | Nov 10, 2026 |
| Chernett Jorey | 10% owner | Buy | 8,500 | $54K | Nov 9, 2026 |
| Chernett Jorey | 10% owner | Sale | 11,265 | $69K | Nov 6, 2026 |
| Chernett Jorey | 10% owner | Buy | 14,000 | $104K | Oct 19, 2026 |
| Black Jeffrey G. | officer | Sale | 20,614 | $149K | Sep 1, 2026 |
| Black Jeffrey G. | officer | Buy | 1,571 | $5K | Sep 1, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
19.6%
3yr Revenue CAGR
13.5%
EPS Growth YoY
-12.05%
FCF Growth YoY
-3.4%
Revenue Trend
ACCELERATING
SEPT Investing tracks real-time dark pool institutional trades for XGN, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 24:59:01 | $4.93 | 1,906 | $$9K | BUY |
| 21:00:00 | $5.04 | 35,992 | $$181K | MIDPOINT |
| 20:58:51 | $5.02 | 5,000 | $$25K | BUY |
| 20:58:45 | $5.01 | 1,000 | $$5K | MIDPOINT |
| 20:58:15 | $5.01 | 5,000 | $$25K | SELL |
5 dark pool trades shown · $$246K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT Investing provides real-time options flow tracking for XGN, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| PUT | $5 | Nov 20 | 9 | $$150 | 3 | SWEEP |
1 options trades shown · 0% calls
Unusual activity, GEX levels, max pain, and dealer positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for EXAGEN INC. (XGN) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (8 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →EXAGEN INC. (XGN) is at $5.04, down 4.28% (-$0.22) at the Nov 11, 2026 close.
Nov 10, 2026: Exagen shares plunged 18.88% to close at $5.07 after the company filed a prospectus for a $150 million mixed shelf offering, raising dilution concerns. The selloff was compounded by third-quarter results showing a per-share loss of $0.25, wider than the $0.18 analysts expected, though revenue of $18.417 million slightly beat the $18.343 million consensus.
The average analyst price target for XGN is $11.00, ranging from $8 to $12, based on 5 analysts. Latest: Canaccord Genuity maintains on Oct 19, 2026.
Analyst ratings for XGN: 1 Buy, 6 Hold, 0 Sell — consensus Hold.
XGN last reported on Nov 10, 2026: EPS -$0.25 vs -$0.18 expected — a miss of 38.9%.
XGN does not currently pay a dividend.
EXAGEN INC. reported $23M of debt and $25M of cash (Jun 30, 2026).
Support: $4.09, $2.82. Resistance: $5.11, $7.05, $7.99.
Insider activity: SELLING, 1 buys and 4 sells in the last 90 days.
Nov 12, 2026: Exagen Inc. filed an insider trading report (Form 4) · Nov 12, 2026: Holder of 10% stake in Exagen flags short-swing trade profit · Nov 11, 2026: Canaccord Genuity keeps Buy rating on Exagen, cuts price target to $9